Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)

Dermatitis, Atopic Clinical Trial

— DESSINE2  

Official title:

Determining Effects of Superfine Sheep Wool in INfantile Eczema (DESSINE 2): a Multicentre Randomized Crossover Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04011215
• Other study ID #: 2019.034
• Status: Recruiting
• Phase: N/A
• Start date: September 23, 2019
• Est. completion date: October 2024

Study information

• Verified date: October 2023
• Source: Murdoch Childrens Research Institute
• Contact: John C Su, FACD, FRACP
• Phone: +61393871000
• Email: john.su[@]mcri.edu.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a sequentially recruited, cross-over-cohort, outpatient-based evaluation of the effectiveness of wool clothing, as compared to standard clothing, in reducing the severity of childhood atopic dermatitis (eczema) over two consecutive six-week periods.

Description:

The study will aim for a sample size of approximately 150 participants (equally distributed between 3 international sites) between the ages of 3 months and 5 years referred to the respective Dermatology Departments for management of moderate to severe atopic dermatitis. They will be sequentially recruited and randomized to the wool-to-standard clothing arm or standard clothing-to-wool arm. The study will run for 12 weeks for each participant with two consecutive 6-week periods for each intervention, either of wool followed by standard clothing or standard followed by wool clothing. Participants will be assessed by a blinded trained researcher, at their initial appointment, 3 weeks, 6 weeks, 9 weeks and 12 weeks post commencement of the first intervention. The primary outcome is the severity of atopic dermatitis at 6 weeks post commencement of each intervention i.e.at week 6 and week 12. Severity of atopic eczema will be measured using the Eczema Area and Severity Index (EASI). Secondary outcomes include the severity and change in the severity of eczema using the EASI at 3 weeks, the validated Investigators Global Assessment for atopic dermatitis (vIGA-AD™) score and quality of life assessment using the children's Dermatology Life Quality Index (cDLQI) at 3 and 6 weeks of each 6 week intervention period, as well as weekly Patient Oriented SCORing Atopic Dermatitis index (PO-SCORAD) scores.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Months to 5 Years

Eligibility

Inclusion Criteria:

• Is aged between 3 months and 5 years of age at the time of recruitment
• Has moderate to severe eczema as determined by an EASI score of 7 or above at their initial visit
• Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participants behalf

Exclusion Criteria:

• Has a known allergic contact dermatitis to wool or merino wool
• Is unable to attend all scheduled visits
• Has unstable eczema defined by an escalation of treatment requirements during the preceding 6 weeks. This would include flares of AD for any reason including infection, food allergy etc.
• Use of systemic corticosteroids within 6 weeks of study start.
• Any medical reason that is considered by the principal investigator to preclude enrolment.

Related Conditions & MeSH terms

• Dermatitis
• Dermatitis, Atopic

Intervention

Other:
• wool clothing
superfine merino wool ensembles for baby/child wear
• standard clothing
Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.

Locations

Country	Name	City	State
United States	Northwestern University, Skin Disease Research Center, Lurie Children's Hospital	Chicago	Illinois

Sponsors (4)

Lead Sponsor	Collaborator
Murdoch Childrens Research Institute	Australian Wool Innovation Ltd, Northwestern University, United Christian Hospital

Country where clinical trial is conducted

United States, 

References & Publications (1)

Su JC, Dailey R, Zallmann M, Leins E, Taresch L, Donath S, Heah SS, Lowe AJ. Determining Effects of Superfine Sheep wool in INfantile Eczema (DESSINE): a randomized paediatric crossover study. Br J Dermatol. 2017 Jul;177(1):125-133. doi: 10.1111/bjd.15376. Epub 2017 Jun 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Eczema Area and Severity Index (EASI)	blinded assessor administered EASI (units on a scale), will assess change from baseline. A score is obtained ranging from 0-72 based on erythema, papulation, excoriation and lichenification, each graded 0-3 for each of four body regions (head and neck, upper limbs, trunk, lower limbs) that are weighted according to surface area representation. A higher number indicates increased severity.	week 3 of each 6 week period (ie week 6 and 12)
Secondary	Eczema Area and Severity Index (EASI)	blinded assessor administered EASI (units on a scale), will assess change from baseline.	week 3 of each 6 week period (ie week 3 and 9)
Secondary	validated Investigators Global Assessment for atopic dermatitis (vIGA-AD™) score	blinded assessor administered vIGA-AD™ score (units on a scale), will assess change from baseline. This score assesses erythema, induration/papulation, lichenification and oozing/crusting on ascale of 0 to 4. A high score reflects greater severity.	week 3, 6, 9, 12
Secondary	children's Dermatology Life Quality Index (cDLQI)	patient administered cDLQI questionnaire (units on a scale), will assess change from baseline. Ten questions are each scored from 0 to 3, the total score ranging from 0-30. A higher score reflects greater impairment of quality of life.	week 3, 6, 9, 12
Secondary	Patient Oriented SCORing Atopic Dermatitis score (PO-SCORAD)	patient completed PO-SCORAD score (units on a scale). It measures global severity using a scale ranging from 0 to 103, based on disease extent, six morphological parameters and two subjective markers (itch and sleep disturbance). High scores reflect greater severity.	weekly over 12 weeks
Secondary	Topical medication use	questionnaire (number of times per day medication is applied; the name and strength of medication will be noted). This will be compared with baseline use.	daily over 12 weeks
Secondary	Topical moisturiser use	questionnaire to determine number of times per day moisturiser is applied. This will be compared with baseline use.	weekly over 12 weeks